UA96257C2 - Стабілізована фармацевтична композиція лейкотриєн-b4 (ltb4) агента - Google Patents

Стабілізована фармацевтична композиція лейкотриєн-b4 (ltb4) агента

Info

Publication number
UA96257C2
UA96257C2 UAA200704260A UAA200704260A UA96257C2 UA 96257 C2 UA96257 C2 UA 96257C2 UA A200704260 A UAA200704260 A UA A200704260A UA A200704260 A UAA200704260 A UA A200704260A UA 96257 C2 UA96257 C2 UA 96257C2
Authority
UA
Ukraine
Prior art keywords
ltb4
pharmaceutical formulation
leukotriene
stabilized
agent pharmaceutical
Prior art date
Application number
UAA200704260A
Other languages
English (en)
Russian (ru)
Inventor
П'єр Боржа
Original Assignee
Лтб4 Свіден Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лтб4 Свіден Аб filed Critical Лтб4 Свіден Аб
Publication of UA96257C2 publication Critical patent/UA96257C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Даний винахід стосується нової фармацевтичної композиції, що містить LTB4 агент при лужній рН, ефективній для стабілізації LTB4 агента, та являє собою композицію з підвищеним терміном придатності. Композиція за даним винаходом має підвищений термін придатності, переважно щонайменше 24 місяці.
UAA200704260A 2004-09-20 2005-09-20 Стабілізована фармацевтична композиція лейкотриєн-b4 (ltb4) агента UA96257C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61096204P 2004-09-20 2004-09-20
US63500904P 2004-12-13 2004-12-13
US63548204P 2004-12-14 2004-12-14
PCT/IB2005/002781 WO2006032977A2 (en) 2004-09-20 2005-09-20 Stabilized leukotriene b4 (ltb4) agent pharmaceutical

Publications (1)

Publication Number Publication Date
UA96257C2 true UA96257C2 (uk) 2011-10-25

Family

ID=35902513

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200704260A UA96257C2 (uk) 2004-09-20 2005-09-20 Стабілізована фармацевтична композиція лейкотриєн-b4 (ltb4) агента

Country Status (22)

Country Link
US (1) US8664271B2 (uk)
EP (1) EP1796730B1 (uk)
JP (1) JP4767256B2 (uk)
KR (1) KR101109735B1 (uk)
CN (1) CN101039698B (uk)
AT (1) ATE474603T1 (uk)
AU (1) AU2005286161B2 (uk)
BR (1) BRPI0516957A (uk)
CA (1) CA2581156C (uk)
CY (1) CY1110841T1 (uk)
DE (1) DE602005022462D1 (uk)
DK (1) DK1796730T3 (uk)
EA (1) EA012982B1 (uk)
ES (1) ES2349410T3 (uk)
NO (1) NO20071977L (uk)
NZ (1) NZ553982A (uk)
PL (1) PL1796730T3 (uk)
PT (1) PT1796730E (uk)
SI (1) SI1796730T1 (uk)
TW (1) TWI361078B (uk)
UA (1) UA96257C2 (uk)
WO (1) WO2006032977A2 (uk)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1840114A1 (en) * 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
CN102435443B (zh) * 2011-09-08 2014-04-02 中国汽车技术研究中心 汽车催化器快速老化数据采集系统
JP6483593B2 (ja) * 2015-03-06 2019-03-13 アークレイ株式会社 血液検査装置および血液検査方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179959A1 (en) * 1982-04-20 1986-05-07 Merck Frosst Canada Inc. Conjugates of leukotrienes with proteins
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4876505A (en) * 1988-05-27 1989-10-24 Westinghouse Electric Corp. Apparatus and method for monitoring steam turbine shroud clearance
US20040132820A1 (en) 1996-02-15 2004-07-08 Jean Gosselin Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US5909734A (en) * 1996-12-03 1999-06-08 Regents Of The University Of Michigan Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
CA2452008C (en) * 2001-07-05 2012-03-06 Virocell Inc. Ltb4 as vaccine adjuvant
WO2003105823A1 (en) * 2002-06-14 2003-12-24 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth

Also Published As

Publication number Publication date
DE602005022462D1 (de) 2010-09-02
KR20070085277A (ko) 2007-08-27
EA200700676A1 (ru) 2007-10-26
PL1796730T3 (pl) 2010-12-31
BRPI0516957A (pt) 2008-09-30
CN101039698A (zh) 2007-09-19
TW200626175A (en) 2006-08-01
TWI361078B (en) 2012-04-01
AU2005286161B2 (en) 2010-09-09
US20060063837A1 (en) 2006-03-23
EP1796730A2 (en) 2007-06-20
EA012982B1 (ru) 2010-02-26
NO20071977L (no) 2007-04-18
ES2349410T3 (es) 2011-01-03
JP4767256B2 (ja) 2011-09-07
CY1110841T1 (el) 2015-06-10
JP2008513431A (ja) 2008-05-01
CN101039698B (zh) 2011-11-09
PT1796730E (pt) 2010-10-26
ATE474603T1 (de) 2010-08-15
WO2006032977A2 (en) 2006-03-30
WO2006032977A3 (en) 2006-07-13
CA2581156C (en) 2011-07-12
NZ553982A (en) 2009-09-25
HK1103652A1 (en) 2007-12-28
US8664271B2 (en) 2014-03-04
CA2581156A1 (en) 2006-03-30
SI1796730T1 (sl) 2010-12-31
DK1796730T3 (da) 2010-11-01
KR101109735B1 (ko) 2012-02-17
AU2005286161A1 (en) 2006-03-30
EP1796730B1 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
EP1247456A3 (en) Palatable pharmaceutical compositions for companion animals
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
WO2002051424A8 (en) Drugs against articular failure
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
IL163366A (en) Glucocorticoid mimetics, pharmaceutical compositions thereof and uses thereof for the preparation of pharmaceutical compositions
WO2005065657A3 (en) Solid compositions of low-solubility drugs and poloxamers
WO2004014143A8 (en) Compositions and process for delivering an additive
WO2006127069A3 (en) A delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
WO2003080070A3 (en) Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
SG143257A1 (en) Pregabalin composition
WO2005007115A3 (en) Pharmaceutical composition for inhibiting acid secretion
NZ547587A (en) Pharmaceutical compositions and methods for insulin treatment
AU2003221524A1 (en) Administration form for oral administration of active ingredients, vitamins and/or nutrients
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
IL192611A0 (en) Biologically active composition comprising ethylcellulose
TW200738283A (en) Formulations of conjugated estrogens and bazedoxifene
IL133004A0 (en) Pharmaceutical compositions comprising an aldose inhibitor and an ace inhibitor
WO2005074925A8 (en) Compositions substantially free of galactomannan containing piperacillin and tazobactam
WO2004039326A3 (en) Propofol with cysteine
NO20071977L (no) Stabilisert farmasoytisk formulering av leukotrien b4 (ltb4)-middel
WO2001085188A3 (en) Use of echinacea as a hematinic agent
WO2006109175A3 (en) Solid dosage form of an antidiabetic drug